40.39

1.75% -0.72

After Hours: 39.00 -1.39 -3.44%

Protagonist Therapeutics Inc (PTGX)

Overview News Price History Option Chain Financials Why PTGX Down? Discussions Forecast

Protagonist Therapeutics Inc stock is traded at $40.39, with a volume of 476.55K. It is down -1.75% in the last 24 hours and down -14.01% over the past month. Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.

Previous Close:

$41.11

Open:

$40.98

24h Volume:

476.55K

Relative Volume:

0.82

Market Cap:

$2.41B

Revenue:

$45.48M

Net Income/Loss:

$169.95M

P/E Ratio:

-15.07

EPS:

-2.68

Net Cash Flow:

$230.85M

1W Performance:

-13.14%

1M Performance:

-14.01%

6M Performance:

+31.39%

1Y Performance:

+140.27%

1-Day Range:

$39.70

$41.05

1-Week Range:

$39.41

$46.64

52-Week Range:

$16.63

$48.89

Protagonist Therapeutics Inc Stock (PTGX) Company Profile

Name

Protagonist Therapeutics Inc

Sector

Healthcare (1196)

Industry

Biotechnology (683)

Phone

(510) 474-0170

Address

7707 GATEWAY BLVD., SUITE 140, NEWARK, CA

Employee

126

Twitter

Next Earnings Date

2024-11-04

Latest SEC Filings

PTGX's Discussions on Twitter

Compare PTGX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PTGX	40.39	2.41B	45.48M	169.95M	230.85M	-2.68
VRTX	467.01	119.87B	10.63B	-479.80M	-1.35B	13.33
REGN	762.00	83.27B	13.85B	4.65B	3.32B	35.06
ARGX	567.90	33.96B	1.86B	-40.29M	-1.28B	-4.16
ALNY	232.27	30.18B	2.09B	-332.26M	16.06M	-4.14
BNTX	101.87	24.42B	3.30B	-501.07M	1.03B	11.54

Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-25-23	Resumed	Jefferies	Buy
Aug-25-22	Initiated	JMP Securities	Mkt Outperform
Feb-11-22	Initiated	BTIG Research	Buy
Oct-12-21	Upgrade	JP Morgan	Neutral → Overweight
Oct-11-21	Upgrade	Northland Capital	Market Perform → Outperform
Sep-20-21	Downgrade	JP Morgan	Overweight → Neutral
May-24-21	Initiated	JMP Securities	Mkt Outperform
May-24-21	Initiated	Northland Capital	Outperform
Jan-06-21	Initiated	JP Morgan	Overweight
Dec-16-20	Initiated	Piper Sandler	Overweight
Sep-18-20	Reiterated	H.C. Wainwright	Buy
Jul-15-20	Initiated	Jefferies	Buy
May-18-20	Reiterated	H.C. Wainwright	Buy
Jul-08-19	Initiated	H.C. Wainwright	Buy
May-09-19	Upgrade	Stifel	Hold → Buy
Dec-06-18	Initiated	Nomura	Buy
Jan-29-18	Initiated	Stifel	Buy
Jul-21-17	Initiated	BTIG Research	Buy

View All

Protagonist Therapeutics Inc Stock (PTGX) Latest News

Nov 18, 2024

Protagonist Announces Positive Topline Results From Phase 3 ICONIC Studies of Icotrokinra (JNJ-2113), a First-in-Class Investigational Targeted Oral Peptide That Selectively Blocks the IL-23 Receptor in Plaque Psoriasis - WSIL TV

Nov 18, 2024

Protagonist Therapeutics Enters Oversold Territory (PTGX) - Nasdaq

Nov 18, 2024

Protagonist's Psoriasis Drug Shows 74% Success Rate, Secures $165M Milestone Payment | PTGX Stock News - StockTitan

Nov 18, 2024

Nov 17, 2024

Janney Montgomery Scott LLC Takes Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat

Nov 17, 2024

Nov 16, 2024

Amalgamated Bank Buys 15,301 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World

Nov 16, 2024

Nov 15, 2024

Protagonist Therapeutics (PTGX) Upgraded to Buy: Here's What You Should Know - Yahoo Finance

Nov 13, 2024

HC Wainwright Issues Pessimistic Estimate for PTGX Earnings - MarketBeat

Nov 13, 2024

US Bancorp DE Lowers Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World

Nov 13, 2024

Nov 11, 2024

Protagonist Therapeutics (NASDAQ:PTGX) Earns Buy Rating from HC Wainwright - MarketBeat

Nov 11, 2024

Nov 10, 2024

New York State Teachers Retirement System Invests $1.11 Million in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat

Nov 10, 2024

New York State Teachers Retirement System Makes New Investment in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World

Nov 10, 2024

Protagonist Therapeutics (NASDAQ:PTGX) Sets New 12-Month High – Should You Buy? - Defense World

Nov 10, 2024

Nov 09, 2024

Creative Planning Acquires New Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World

Nov 09, 2024

Nov 08, 2024

What is Wedbush’s Forecast for PTGX Q3 Earnings? - Defense World

Nov 08, 2024

Protagonist Therapeutics (NASDAQ:PTGX) Sets New 52-Week HighWhat's Next? - MarketBeat

Nov 08, 2024

Protagonist Therapeutics earnings beat by $0.04, revenue topped estimates - Investing.com UK

Nov 08, 2024

Nov 07, 2024

What is Wedbush's Estimate for PTGX Q3 Earnings? - MarketBeat

Nov 07, 2024